INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 54 filers reported holding INOZYME PHARMA INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,456,333 | +0.5% | 822,823 | +33.3% | 0.00% | – |
| Q2 2023 | $3,439,246 | +148.8% | 617,459 | +156.0% | 0.00% | – |
| Q1 2023 | $1,382,121 | +566343.0% | 241,208 | +3.5% | 0.00% | – |
| Q4 2022 | $244 | -100.0% | 233,126 | -0.2% | 0.00% | – |
| Q3 2022 | $626,000 | -39.5% | 233,685 | +7.7% | 0.00% | – |
| Q2 2022 | $1,034,000 | +36.1% | 216,925 | +16.6% | 0.00% | – |
| Q1 2022 | $760,000 | -39.4% | 186,007 | +1.1% | 0.00% | – |
| Q4 2021 | $1,255,000 | -45.5% | 184,019 | -7.4% | 0.00% | – |
| Q3 2021 | $2,302,000 | -24.8% | 198,624 | +10.5% | 0.00% | – |
| Q2 2021 | $3,061,000 | +2.8% | 179,672 | +19.5% | 0.00% | – |
| Q1 2021 | $2,977,000 | +35.5% | 150,361 | +41.3% | 0.00% | – |
| Q4 2020 | $2,197,000 | -14.9% | 106,446 | +8.3% | 0.00% | -100.0% |
| Q3 2020 | $2,583,000 | – | 98,284 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |